Nouscom’s €120M Bet on Cancer Interception: Stopping Tumors Before They Start

BASEL, Switzerland – October 19, 2026 – For decades, the medical community’s approach to hereditary cancer syndromes has been a grim exercise in waiting. Patients with known genetic predispositions are subjected to relentless cycles of surveillance, hoping to catch a tumor early enough to cut it out. Today, Basel-based clinical-stage biotech Nouscom announced an oversubscribed €120 million ($135 million) Series D financing round that signals a definitive shift in this paradigm. The capital injection will fund a global, registration-enabling clinical trial for NOUS-209, an investigational immunotherapy designed not to treat cancer, but to intercept it before it ever forms.

Co-led by M Ventures and Revelation Partners, the round brings together a formidable syndicate of new institutional backers, including the European Investment Bank (EIB), Angelini Industries, and Neva SGR, alongside a roster of existing international life sciences investors. The funding coincides with the presentation of unprecedented long-term clinical data at the European Society of Medical Oncology (ESMO) Congress, demonstrating that NOUS-209 can safely and effectively halt the development of precancerous lesions in individuals with Lynch Syndrome.

The Interception Revolution: Shifting From Treating to Stopping Cancer

To understand the magnitude of Nouscom’s mandate, one must look at the reality of Lynch Syndrome (LS). Affecting over two million carriers globally, LS is the most common hereditary cancer syndrome. It is caused by inherited mutations in specific DNA repair genes, leading to a phenomenon known as mismatch repair deficiency (dMMR). Carriers face up to an 80% lifetime risk of developing colorectal cancer, a 50% risk of endometrial cancer, and elevated risks for a host of other malignancies including gastric, ovarian, and pancreatic cancers.

The current standard of care for these individuals is as archaic as it is invasive. It relies heavily on frequent screenings—such as annual colonoscopies—and prophylactic surgeries, including the elective removal of healthy organs.

"Over two million LS carriers live with up to an 80% lifetime cancer risk and nothing to offer them but surveillance and surgery," said Marina Udier, Ph.D., Chief Executive Officer of Nouscom. "We built Nouscom to change that equation. This financing, alongside the data we are presenting at ESMO, puts us closer to a world where cancer is stopped before it starts. I am grateful to our new and existing investors for backing that conviction, and to the team behind NOUS-209."

The data presented at ESMO by Dr. Eduardo Vilar-Sanchez, Chair ad interim of Clinical Cancer Prevention at The University of Texas MD Anderson Cancer Center, provides the first clinical validation of this interception hypothesis. According to the Phase 1b/2 trial results, all evaluable Lynch Syndrome carriers dosed with NOUS-209 remained entirely free of advanced adenomas and colorectal cancer after one year (n=43) and two years (n=17) of follow-up.

When benchmarked against the natural history of the disease, these results are staggering. In a standard Lynch Syndrome population, the median age for a first colorectal adenoma diagnosis is just 40.3 years, and adenoma detection rates during routine colonoscopies hover around 20%. Furthermore, Lynch-associated polyps can aggressively progress to invasive cancer in just two to three years—a fraction of the decade it often takes for sporadic tumors to develop. The complete absence of advanced adenomas in the NOUS-209 cohort represents a profound disruption of this timeline.

Cracking the Frameshift Code: The Off-the-Shelf Advantage

The science underpinning NOUS-209 represents a masterclass in exploiting a tumor’s genetic vulnerabilities. Tumors characterized by mismatch repair deficiency (dMMR) and microsatellite instability (MSI) accumulate specific genetic errors. These errors result in the creation of frameshift peptide (FSP) neoantigens—unique markers that are highly immunogenic, present on precancerous and cancerous cells, but entirely absent in healthy tissue.

While mRNA giants like Moderna and BioNTech have captured the public imagination with personalized neoantigen vaccines—custom-built therapies requiring individual tumor sequencing and bespoke manufacturing for each patient—Nouscom has taken a decidedly different, and arguably more scalable, route.

Nouscom’s researchers identified 209 shared FSP neoantigens that consistently appear across dMMR/MSI-H tumors. By packaging these 209 shared neoantigens into two proprietary viral vectors (a gorilla adenoviral vector and a modified vaccinia Ankara vector), Nouscom created an "off-the-shelf" immunotherapy. This approach bypasses the costly, slow bottleneck of personalized manufacturing, allowing the vaccine to be administered proactively to train the immune system to hunt down and destroy cells expressing these specific mutations before they coalesce into a malignant tumor.

The Phase 1b/2 data, recently published in Nature Medicine, confirmed that NOUS-209 drives broad, potent, and durable anti-neoantigen T-cell responses, which are further enhanced by annual re-treatment.

Betting Big on Prevention: The Syndicate and the Strategy

Raising €120 million in a Series D round for a preventive oncology asset is no small feat. The biopharmaceutical industry has traditionally been hesitant to fund cancer interception due to the notoriously long trial timelines and complex regulatory hurdles associated with proving a drug prevents something from happening.

However, Nouscom has systematically de-risked this pathway. The U.S. Food and Drug Administration (FDA) has already granted NOUS-209 Fast Track designation. More importantly, Nouscom has secured regulatory alignment with both the FDA and the European Medicines Agency (EMA) to use "event-free survival"—which includes the formation of precancerous lesions—as the primary endpoint for its upcoming global registration-enabling trial. This regulatory flexibility is a watershed moment, signaling that global health authorities are ready to embrace and evaluate true cancer interception.

"What sets Nouscom apart is its unique cancer interception approach and the platform that enables it," said Dr. Hakan Goker, Managing Director and Head of Biotechnology Investments at M Ventures. "Maturing clinical evidence and a regulatory-aligned path into a registration-enabling trial in such an unchartered space is a rare combination for a private biotech company and the commitment of the investor syndicate underpins this deep conviction."

The composition of the syndicate further underscores the broad strategic implications of Nouscom’s work. The participation of the European Investment Bank (EIB) through its Aurea co-investment facility points to the profound public health and economic benefits of a preventive cancer vaccine. Treating late-stage metastatic colorectal cancer is a massive drain on global healthcare systems; intercepting it with an off-the-shelf vaccine offers a compelling pharmacoeconomic value proposition.

Similarly, the involvement of Angelini Industries highlights the growing intersection of traditional industrial healthcare and cutting-edge biotech. "Angelini Industries is becoming an increasingly innovation-driven group competing on a global scale, bringing together the search for companies set to shape the future of healthcare with the research and pharmaceutical assets of our industrial heritage," said Sergio Marullo di Condojanni, Chief Executive Officer of Angelini Industries. "We see significant potential in Nouscom’s pioneering approach to cancer prevention in Lynch Syndrome and we are proud to support its outstanding team."

A New Economic Paradigm for Hereditary Healthcare

As Nouscom prepares to initiate its pivotal trial, the implications extend far beyond the two million individuals living with Lynch Syndrome. If NOUS-209 successfully navigates the regulatory gauntlet, it will establish a blueprint for immunoprevention in other high-risk genetic profiles, fundamentally altering the economics of hereditary healthcare.

"This significant financing reflects the confidence of our investors in Nouscom’s vision, team and the transformative potential of cancer interception," said Göran Ando, M.D., Independent Chair of the Board of Nouscom. "With this backing, we are well positioned to accelerate NOUS-209’s clinical development and our commitment to those living with Lynch Syndrome. I am delighted to welcome our new investors, whose support further strengthens Nouscom as we enter this next chapter."

For decades, the biotechnology sector has focused its immense resources on extending life by months in late-stage metastatic settings. Nouscom’s €120 million raise represents a bold, well-capitalized pivot toward a more ambitious goal: utilizing the immune system’s innate memory to ensure the tumor never arrives at all.